The National Organization for Rare Disorders (NORD) commended the sixth drug user fee agreement, released July 15, for its potential benefits to the rare disease community, but a NORD official told Inside Health Policy that the group will work with lawmakers to offer amendments to the bill. In a press statement NORD highlighted the potential positive impact of PDUFA's expansion of FDA's Rare Diseases Program (RDP). Under PDUFA VI specialists from the rare disease program will be incorporated into...